argenx delivered $1.5 billion in second-quarter VYVGART product sales and entered the second half with two registrational study readouts expected before year-end.
Key Investor Takeaways
- argenx (NASDAQ:ARGX) reported second-quarter product net sales of $1.52 billion, up 60% year over year and 17% sequentially.
- Operating profit more than doubled to $494 million, while diluted earnings per share increased to $7.32.
- The expanded VYVGART label now covers all adult generalized myasthenia gravis serotypes in the United States.
- Registrational myositis and multifocal motor neuropathy results are expected in the third and fourth quarters, respectively.
- Cash, cash equivalents and current financial assets rose to $5.2 billion, providing funding capacity for commercial expansion and pipeline development.
Why ARGX Stock Is in Focus
argenx SE (NASDAQ:ARGX) generated second-quarter product net sales of $1.52 billion, compared with $949 million in the same period of 2025.
Total operating income rose to $1.54 billion from $967 million, while operating profit increased to $494 million from $201 million. Quarterly profit reached $472 million, up from $245 million, and diluted EPS climbed to $7.32 from $3.74.
For the first half of 2026, VYVGART product net sales reached $2.81 billion, compared with $1.74 billion a year earlier. Six-month operating profit increased to $887 million, while profit for the period was $838 million.
Commercial momentum was supported by the US launch of VYVGART and VYVGART Hytrulo for anti-AChR antibody-negative generalized myasthenia gravis. The expanded label now includes anti-AChR-positive, anti-MuSK-positive, anti-LRP4-positive and triple-seronegative patients.
The company is also preparing to expand VYVGART into ocular myasthenia gravis following positive ADAPT OCULUS results. A subcutaneous autoinjector remains positioned for a 2027 launch across approved indications.
Why This Matters for Investors
The 60% increase in quarterly VYVGART sales suggests argenx is continuing to expand its commercial base while moving beyond its initial patient population.
Broadening the treatment label to all adult gMG serotypes may increase the number of eligible patients and simplify how physicians position the therapy within the disease market. Continued uptake will be important in determining whether the current sales trajectory can be sustained.
The company is also becoming increasingly profitable despite significantly higher research and commercial investment. Research and development spending rose to $486 million from $330 million, while selling, general and administrative expenses increased to $417 million from $325 million.
Those increases reflect the scale of argenx’s registrational programme and global VYVGART commercialisation. However, the company’s $5.2 billion liquidity position and $700 million of first-half operating cash flow may reduce near-term financing risk as it advances multiple late- and early-stage assets.
The next phase of the investment case may increasingly depend on whether argenx can convert VYVGART from a successful autoimmune franchise into a broader multi-indication platform.
Pipeline Catalysts Could Broaden the Growth Story
Topline results from the registrational ALKIVIA study in autoimmune myositis are expected during the third quarter of 2026. A positive result could support VYVGART’s expansion into rheumatology and provide another potential labelled indication.
Results from the EMPASSION study of empasiprubart in multifocal motor neuropathy are expected in the fourth quarter. Empasiprubart is positioned as argenx’s second “pipeline-in-a-product” opportunity and is also being studied in CIDP and as an add-on therapy to VYVGART in gMG.
The company is simultaneously progressing future FcRn candidates. ARGX-213 is described as Phase 3 ready and designed for monthly dosing, while ARGX-124 is expected to complete Phase 1 evaluation by the end of 2026.
By year-end, argenx expects to have ten molecules in clinical development. This could reduce long-term dependence on a single asset, although most of the emerging programmes remain subject to clinical development risk.
What to Watch Next
The ALKIVIA myositis readout in the third quarter will be the nearest major clinical catalyst.
Investors will then turn to the fourth-quarter EMPASSION results to assess whether empasiprubart can emerge as a second meaningful commercial franchise.
Further VYVGART sales growth, adoption across seronegative gMG patients and progress toward the planned 2027 autoinjector launch will also help determine whether argenx remains on track toward its Vision 2030 targets.